- Home
- ORI vs BBIO Comparison
ORI vs BBIO Comparison
Compare ORI & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORI
- BBIO
- Stock Information
- Founded
- ORI 1923
- BBIO 2015
- Country
- ORI United States
- BBIO United States
- Employees
- ORI N/A
- BBIO N/A
- Industry
- ORI Property-Casualty Insurers
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ORI Finance
- BBIO Health Care
- Exchange
- ORI Nasdaq
- BBIO Nasdaq
- Market Cap
- ORI 9.9B
- BBIO 9.4B
- IPO Year
- ORI N/A
- BBIO 2019
- Fundamental
- Price
- ORI $43.51
- BBIO $56.50
- Analyst Decision
- ORI Strong Buy
- BBIO Strong Buy
- Analyst Count
- ORI 2
- BBIO 16
- Target Price
- ORI $47.00
- BBIO $64.44
- AVG Volume (30 Days)
- ORI 1.4M
- BBIO 2.2M
- Earning Date
- ORI 10-23-2025
- BBIO 11-11-2025
- Dividend Yield
- ORI 2.67%
- BBIO N/A
- EPS Growth
- ORI 48.63
- BBIO N/A
- EPS
- ORI 3.53
- BBIO N/A
- Revenue
- ORI $8,666,400,000.00
- BBIO $235,812,000.00
- Revenue This Year
- ORI $8.95
- BBIO $115.46
- Revenue Next Year
- ORI $5.88
- BBIO $65.03
- P/E Ratio
- ORI $12.34
- BBIO N/A
- Revenue Growth
- ORI 14.20
- BBIO 7.62
- 52 Week Low
- ORI $33.00
- BBIO $21.72
- 52 Week High
- ORI $44.00
- BBIO $57.47
- Technical
- Relative Strength Index (RSI)
- ORI 71.01
- BBIO 65.45
- Support Level
- ORI $42.99
- BBIO $52.97
- Resistance Level
- ORI $43.42
- BBIO $55.33
- Average True Range (ATR)
- ORI 0.67
- BBIO 1.59
- MACD
- ORI 0.01
- BBIO 0.28
- Stochastic Oscillator
- ORI 83.53
- BBIO 88.84
About ORI Old Republic International Corporation
Old Republic International Corp offers a diverse range of specialized insurance products to individuals and institutions. The company operates in two segments: Specialty Insurance and Title Insurance. The Insurances provided by the company includes Automobile Extended Warranty Insurance, Aviation, Commercial Automobile Insurance, Inland Marine, Travel Accident, Workers' Compensation, Financial Indemnity, and others.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.